Company news

Immunocore Holdings PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma

November 6, 2026

Immunocore reports third quarter financial results and provides a business update

November 6, 2026

Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting

October 29, 2026

Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes

October 15, 2026

Calls

The 5 newest of 7 calls. Every call is listed under its year.

Decks

The 5 newest of 15 decks. Every deck is listed under its year.